Pharmaceuticals News & Press Release Distribution

Tycoon Group Announces 2023 Interim Results

The Group's Revenue Hits New Heights Net profit for 1H2023 increased more than 2.8 times YoY Benefited from the Full Resumption of Normal Travel Revenue Continues to Generate Profit in Future Results Highlights * Since the full resumption of normal travel between Hong Kong, Macau and Mainland C...

2023-08-31 13:28 3826

Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

* Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intravenous infusion at escalating dosages. * All cohorts demonstrated a strong safety profile with no dose-limiting toxicity noted for any dosing cohort and the treated patients exhibited encouraging...

2023-08-31 11:30 4253

Sirnaomics Announces 2023 Interim Results

Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global Leadership in RNAi Therapeutics Business Highlights Promising progress in clinical development * After an End of Phase-II meeting and with guidance from the U.S. FDA, the Group is advancing the l...

2023-08-31 10:40 3867

LOTTE BIOLOGICS Holds 'ESG Declaration Ceremony'

* Announces Human Rights and Environmental Management Charter Alongside Annual Implementation Strategies within its Mid-to-Long-term ESG Roadmap * Strengthens Eco-friendly Policies, Including Greenhouse Gas Reduction Plans from the Initial Factory Design Stage SEOUL, South Korea, Aug. 30, 20...

2023-08-31 09:00 1490

LOTTE BIOLOGICS Holds 'ESG Declaration Ceremony'

The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

* Japanese Ministry of Health, Labor and Welfare grants Orphan Drug Designation to tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN) FLORENCE, Italy and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagno...

2023-08-30 23:15 1909

European Society of Cardiology Congress: Traditional Chinese Medicine Qili Qiangxin significantly reduces the risk of cardiovascular death and re-hospitalization due to heart failure

AMSTERDAM, Aug. 30, 2023 /PRNewswire/ -- The latest study indicates that adding TCM Qili Qiangxin Capsules (developed and produced by Yiling Pharmaceutical) to the standard of care for heart failure can significantly reduce the risk of re-hospitalization due to worsening heart failure and cardio...

2023-08-30 20:11 1281

European Society of Cardiology Congress: Traditional Chinese Medicine Qili Qiangxin significantly reduces the risk of cardiovascular death and re-hospitalization due to heart failure

Igniting Innovation, Catalyzing Changes: Bio Farma x MIT Hacking Medicine Hackathon Celebrates Success

JAKARTA, Indonesia, Aug. 30, 2023 /PRNewswire/ -- Bio Farma , Indonesia's state-owned pharmaceutical company, has successfully concluded theBio Farma x MIT Hacking Medicine on August 24 to 27, 2023 in Bali. Over the course of four days, the Hackathon oversaw 200 chos...

2023-08-30 16:16 1404

Igniting Innovation, Catalyzing Changes: Bio Farma x MIT Hacking Medicine Hackathon Celebrates Success

GC Biopharma to organize "Donate Blood with Love", a healthy way of giving back to the community

With the participation of all affiliated group entities YONGIN, South Korea, Aug. 30, 2023 /PRNewswire/ --All executives and employees of GC Biopharma, a South Korean biopharmaceutical company, rolled up their sleeves to practice ESG and social value. On Aug. 30th, the company held the "Donate...

2023-08-30 16:05 1159

Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

SHANGHAI, Aug. 30, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the National Medical Products Adm...

2023-08-30 14:19 1264

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approv...

2023-08-30 11:00 1537

Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure

SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023. (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue ofRMB21.395 bi...

2023-08-30 10:53 2370

Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF

—During the reporting period, Akeso's revenue was RMB3,676.9 million, an increase of 2,154.4% from 2022H1; Akeso recorded a profit ofRMB2,489.5 million. —RMB2,915.2 million was recognized by Akeso as license fee income during the reporting period due to the receipt of an upfront payment equivalen...

2023-08-30 08:03 2053

Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023

* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...

2023-08-30 00:04 1492

Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023

* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...

2023-08-30 00:02 1092

Viva Biotech (1873.HK) Announces 2023 Interim Results：Solid Growth in Main Business, Significant Rebound in Profitability

Highlights of the Interim Results as of June 30, 2023: * Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% * Gross profit amounted to RMB406.0 million, representing a year-on-year increase of approximately 17.7% * Adjusted Non-IFRS net profit amo...

2023-08-29 22:38 2206

Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC

HONG KONG, Aug. 29, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced completion of patient enrollment in a head-to-head study of ivonescimab (AK112, PD-1/VEGF bispecific antibody) compared with pembrolizumab as first-line treatment for patients with PD-L1 positive (PD-L1 TPS≥1%) loca...

2023-08-29 20:00 1146

Bayer Launches Stunting Prevention Program "CETING" for Community of Cisalak, Depok

DEPOK, Indonesia, Aug. 29, 2023 /PRNewswire/ -- Bayer, a global Life Science company in health and nutrition, is taking an active role in addressing the stunting problem inIndonesia. Coinciding with Bayer's 66th year in Indonesia, Bayer launched the CETING (Prevent Stunting) program for the commu...

2023-08-29 13:53 1696

Bayer Launches Stunting Prevention Program

ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference

SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings at the Morgan Stanley 21st Annual Global Healthca...

2023-08-28 20:00 1023

Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines

The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject® (ferric carboxymaltose), for the management of iron deficiency in patients with HF. Phase IV HEART-FI...

2023-08-28 19:00 1988

Harbour BioMed Announces 2023 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...

2023-08-28 17:08 2200